Regeneron (REGN) Withdraws sBLA for Libtayo in Cervical Cancer

Posted byZacks Equity Research Leave a comment on Regeneron (REGN) Withdraws sBLA for Libtayo in Cervical Cancer

Regeneron (REGN) and partner Sanofi voluntarily withdraw the supplemental biologics license application for Libtayo in second-line treatment of advanced cervical cancer.

Leave a comment

Your email address will not be published. Required fields are marked *